Cedrik M. Britten
Chief Tech/Sci/R&D Officer at IMMATICS N.V.
Net worth: 2 M $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Harpreet Singh-Jasuja | M | 50 |
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | 24 years |
| Toni Weinschenk | M | 51 |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | 24 years |
| Steffen Walter | M | 47 |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | 19 years |
| Arnd Christ | M | 57 |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | 4 years |
| Tony Wood | M | - | 7 years | |
| Jesse Goodman | M | 72 | 8 years | |
| Rainer Kramer | M | 60 |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | 12 years |
| Charles Bancroft | M | 65 | 4 years | |
| Michael Atieh | M | 70 | 4 years | |
| Paul Carter | M | 63 | 4 years | |
| Hal Barron | M | 62 | 6 years | |
| Heather Mason | F | 63 | 4 years | |
| Friedrich von Bohlen und Halbach | M | 60 |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | 3 years |
| Carsten Reinhardt | M | 57 |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | 15 years |
| Ephraim Hofsäß | M | - | 5 years | |
| Michael Elmore | M | - | 5 years | |
| Shobie Ramakrishnan | F | - | 6 years | |
| Maria Poulada | F | - | 11 years | |
| Craig Slingluff | M | - |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | - |
| Claudia Blattner | M | - | 9 years | |
| Edward Sturchio | M | - | 4 years | |
| Diana Conrad | F | - | 8 years | |
| Miriam Meyer | M | - | 15 years | |
| Mathias Hothum | M | 58 | 1 years | |
| Maya Martinez-Davis | F | 54 | 4 years | |
| Regis Jean-Pierre Simard | M | 59 | 6 years | |
| Luke Miels | M | - | 7 years | |
| Jonathan Symonds | M | 66 | 5 years | |
| Harald F. Stock | M | 56 |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | 13 years |
| Jordan Silverstein | M | - | 5 years | |
| Adam Stone | M | 44 | 4 years | |
| Eliot Forster | M | 58 | 4 years | |
| Erich Schlick | M | 72 |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | - |
| Peter Chambré | M | 68 | 12 years | |
| Tamara Louw | F | - | 3 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Thomas Mount | M | - | 7 years | |
| Philip Hampton | M | 70 | 4 years | |
| Moncef Slaoui | M | 64 | 11 years | |
| Andrew Witty | M | 59 | - | |
| Stephanie Burns | M | 69 | 9 years | |
| Saul Charles Klein | M | 53 | 2 years | |
| Balbir Kelly Bisla | F | - | 4 years | |
| Murray Stewart | M | 63 | 17 years | |
| Ravi Rao | M | 55 | 7 years | |
| Anjali Bansal | F | 53 | 6 years | |
| Sarah Elton-Farr | F | - | 4 years | |
| Roy Anderson | M | 76 | 11 years | |
| Daniel Podolsky | M | 70 | 10 years | |
| William Louv | M | - | 21 years | |
| Christopher Gent | M | 75 | 11 years | |
| Dame Cox | F | 64 | 6 years | |
| Simon Dingemans | M | 61 | 8 years | |
| Gerardus Johannes Wijers | M | 74 | 3 years | |
| Robert Carr | M | - | 26 years | |
| Tom de Swaan | M | 78 | 9 years | |
| Iain Mackay | M | 62 | 4 years | |
| Laurie Glimcher | M | 72 | 5 years | |
| Stacey Cartwright | F | 60 | 5 years | |
| Deryck Charles Maughan | M | 76 | 12 years | |
| Vindi Banga | M | 69 | 7 years | |
| Muhammad Al-Hajj | M | 53 | 6 years | |
| Martin Andrews | M | 61 | 10 years | |
| Christopher D. Roberts | M | 54 | - | |
| Edgar Cale | M | 60 | 21 years | |
| Lisa Johnson-Pratt | M | 60 | 6 years | |
| David Parry | M | - | 2 years | |
| David Rowe | M | 57 | 20 years | |
| Lini Pandite | M | 65 | 14 years | |
| Fatima Rangwala | M | 49 | 1 years | |
| Min Li | M | 62 | 6 years | |
| Jane Hughes | M | 50 | 3 years | |
| Hu Li | M | 59 | 19 years | |
| Song Gao | M | 52 | 22 years | |
| Tatyana Staneva | F | - | - | |
| Kim Sablich | F | 55 | 8 years | |
| Amin Khan | M | 61 | 6 years | |
| Abid Ansari | M | 46 | 5 years | |
| Neil Brewis | M | 57 | 8 years | |
| Wladimir Hogenhuis | M | 59 | 6 years | |
| Nancy Valente | M | 66 | 1 years | |
| Karenann Terrell | F | 62 | 4 years | |
| Randy Maddux | M | 62 | 4 years | |
| Simon Harford | M | 64 | 8 years | |
| Christof Hettich | M | 64 | 15 years | |
| Shah Hussain | M | 59 | 9 years | |
| Paolo Augusto Paoletti | M | 73 | 7 years | |
| Birgitte Volck | M | 61 | 2 years | |
| Steve Pascoe | M | - | - | |
| Heidi Kempinski | F | - | 1 years | |
| Romulo Colindres | M | 53 | - | |
| Lon Cardon | M | 58 | 9 years | |
| Deirdre Connelly | F | 63 | 6 years | |
| Stewart Mccallum | M | 58 | 9 years | |
| Lorrie Heinemann | F | - | 4 years | |
| Paul-Peter Tak | M | 64 | 7 years | |
| Jason Gardner | M | 53 | 10 years | |
| Michele LaRussa | F | 54 | 4 years | |
| Tomoko Maeda-Chubachi | M | - | 3 years | |
| Susan Crimmin | F | - | - | |
| Dipal Patel | F | - | 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 74 | 74.00% |
| Germany | 26 | 26.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Cedrik M. Britten
- Personal Network